Changing innovation into a registered product: From concept to regulatory approval

Theriogenology. 2018 May:112:75-81. doi: 10.1016/j.theriogenology.2017.07.001. Epub 2017 Jul 6.

Abstract

Innovation in animal health pharmaceuticals is important to address unmet and underserved medical needs, and often comes from products initially developed for human medicine. The purpose of the review is to help readers understand how breakthroughs from human biotechnology may be developed for use in veterinary medicine, while understanding the key drivers to success, the difficulties of regulatory approval, and the realistic risks and rewards of developing applications for animals. The types of human drugs which may be useful for veterinary applications are reviewed, including examples. The regulatory path is discussed, with a review of the various oversight agencies, and the categories of data required to be submitted, including safety, efficacy, manufacturing, environmental impact and human food safety. In conclusion, the cost, development time, and barriers to innovation in veterinary medical pharmaceuticals are discussed.

Keywords: Clinical trials; Gene therapy; Monoclonal antibodies; Regulatory affairs.

Publication types

  • Review

MeSH terms

  • Animal Welfare
  • Animals
  • Biotechnology
  • European Union
  • Food Safety
  • Humans
  • Legislation, Drug*
  • Technology, Pharmaceutical / legislation & jurisprudence
  • Technology, Pharmaceutical / trends*
  • United States
  • United States Department of Agriculture
  • United States Environmental Protection Agency
  • United States Food and Drug Administration
  • Veterinary Drugs*

Substances

  • Veterinary Drugs